Taiga Biotechnologies, Inc.

Taiga Biotechnologies, Inc. is developing a new class of cell-based therapies utilizing autologous immune cells and allogeneic stem cells

Our Technology

Specific target NOT required
No genetic modification
No expansion of cells
4-hour manufacturing process
Scalable, Reliable, Low Risk

Learn more about our Science

See our Pipeline

Upcoming Milestones

TBX-3400 clinical trials
- Phase 1/2 data for melanoma
- Phase 1/2 data for solid tumors
- Efficacy data for hepatitis B and HPV
Initiation of three additional clinical trials